NCT05487170: An ongoing trial by Ranok Therapeutics (Hangzhou) Co., Ltd.
This trial is ongoing. It must report results 5 months, 3 weeks from now.
Full data
| Full entry on ClinicalTrials.gov | NCT05487170 |
|---|---|
| Title | A Phase 1/2, Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of Chaperone-mediated Protein Degrader RNK05047 in Subjects With Advanced Solid Tumors (CHAMP-1) |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | July 12, 2022 |
| Completion date | June 1, 2025 |
| Required reporting date | June 1, 2026, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | Dec. 5, 2025 |
| Days late | None |